Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).
Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu AW, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Tang X, Yu J, Maher E, Feng H, Yao S, Keegan P, Wang J. Wang Z, et al. Among authors: han b, han l, han z. Future Oncol. 2024 Dec 4:1-8. doi: 10.1080/14796694.2024.2426951. Online ahead of print. Future Oncol. 2024. PMID: 39628302
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.
Zhong J, Fei K, Wu L, Li B, Wang Z, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu AW, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Yao S, Yu J, Cai SL, Cai Y, Xu J, Zhuang W, Luo X, Duan J, Wang J. Zhong J, et al. Among authors: han l. Signal Transduct Target Ther. 2024 Dec 24;9(1):369. doi: 10.1038/s41392-024-02087-6. Signal Transduct Target Ther. 2024. PMID: 39715755 Free article. Clinical Trial.
[Correlation analysis between myopia growth and physical development parameters of school-age children in Shihezi area, Xinjiang Uyghur Autonomous Region].
Bai XQ, Zhang CY, Du R, Ren YY, Li ZS, Yan HG, Wang Z, Zhang XH, Quan XJ, Li J, Han LL, Xu X, Zhou Y, Liu MB, Zhang HY, Li L. Bai XQ, et al. Among authors: han ll. Zhonghua Yu Fang Yi Xue Za Zhi. 2024 Dec 6;58(12):1961-1966. doi: 10.3760/cma.j.cn112150-20240817-00664. Zhonghua Yu Fang Yi Xue Za Zhi. 2024. PMID: 39710475 Chinese.
Halcinonide activates smoothened to ameliorate ischemic stroke injury.
Liu J, Zhao W, Kang J, Li X, Han L, Hu Z, Zhou J, Meng X, Gao X, Zhang Y, Gu Y, Liu X, Chen X. Liu J, et al. Among authors: han l. Life Sci. 2024 Dec 20:123324. doi: 10.1016/j.lfs.2024.123324. Online ahead of print. Life Sci. 2024. PMID: 39710062
13,546 results
You have reached the last available page of results. Please see the User Guide for more information.